Clinical Trial Update: Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) [Phase 2]

View source ↗

Summary

This clinical trial update states that the Phase 2 study of MDV9300 in relapsed or refractory diffuse large B-cell lymphoma has been withdrawn. The withdrawal a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Mediastinal Large B-cell Lymphoma
• Transformed Indolent Lymphoma

Drugs mentioned

• MDV9300

Snippet

Sponsor: Medivation, Inc. | Conditions: Lymphoma, Large B-Cell, Diffuse, Primary Mediastinal Large B-cell Lymphoma | Phase 2 | Status: WITHDRAWN